153 related articles for article (PubMed ID: 37503542)
1. Tyrosine kinase alterations in colorectal cancer with emphasis on the distinct clinicopathological characteristics.
Okano S; Yamashiro Y; Onagi H; Sasa K; Hayashi T; Takahashi M; Sugimoto K; Sakamoto K; Yao T; Saito T
Histopathology; 2023 Nov; 83(5):733-742. PubMed ID: 37503542
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
3. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
4. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
5. An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.
Piton N; Lanic MD; Marguet F; Lamy A; Blanchard F; Guisier F; Viennot M; Salaün M; Thiberville L; Jardin F; Sabourin JC; Ruminy P
Lab Invest; 2021 May; 101(5):648-660. PubMed ID: 33495574
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population.
Ying J; Lin C; Wu J; Guo L; Qiu T; Ling Y; Shan L; Zhou H; Zhao D; Wang J; Liang J; Zhao J; Jiao Y; Lu N; Zhao H
PLoS One; 2015; 10(12):e0144731. PubMed ID: 26678488
[TBL] [Abstract][Full Text] [Related]
7. [Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer].
Bai DY; Zhang HP; Zhong S; Suo WH; Gao DH; Ding Y; Tu JH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):898-903. PubMed ID: 27998465
[No Abstract] [Full Text] [Related]
8. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
9. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
10. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
11. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
12. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
[TBL] [Abstract][Full Text] [Related]
13. Genomic Features of Solid Tumor Patients Harboring
Dai Y; Liu P; He W; Yang L; Ni Y; Ma X; Du F; Song C; Liu Y; Sun Y
Front Oncol; 2022; 12():813158. PubMed ID: 35785159
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
15. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.
Chu YH; Barbee J; Yang SR; Chang JC; Liang P; Mullaney K; Chan R; Salazar P; Benayed R; Offin M; Drilon A; Ladanyi M; Nafa K; Arcila ME
J Mol Diagn; 2022 Jun; 24(6):642-654. PubMed ID: 35430374
[TBL] [Abstract][Full Text] [Related]
18. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
Wang B; Chen R; Wang C; Guo J; Yuan M; Chen H; Xia X; Zhong D
Hum Pathol; 2021 Aug; 114():90-98. PubMed ID: 34019866
[TBL] [Abstract][Full Text] [Related]
20. Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors.
Kurihara T; Suehara Y; Akaike K; Hayashi T; Kohsaka S; Ueno T; Hasegawa N; Takagi T; Sasa K; Okubo T; Kim Y; Mano H; Yao T; Kaneko K; Saito T
Sci Rep; 2020 Oct; 10(1):18724. PubMed ID: 33127954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
